



(51) International Patent Classification:

A61K 31/55 (2006.01) *A61K 9/14* (2006.01)
A61K 31/27 (2006.01) *A61P 25/00* (2006.01)
A61K 9/16 (2006.01)

(21) International Application Number:

PCT/US2012/050148

(22) International Filing Date:

9 August 2012 (09.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/522,811 12 August 2011 (12.08.2011) US

(71) Applicant (for all designated States except US): **PEROSPHERE INC.** [US/US]; 171 Meeting Street, Providence, RI 02912 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAKHURU, Sasha, H.** [US/US]; 200 Exchange Street, Unit 1612, Providence, RI 02903 (US). **LAULICHT, Bryan, E.** [US/US]; 100 Landsdowne Street, Apt. 1501, Cambridge, MA 02139 (US). **MATHIOWITZ, Edith** [US/US]; 184 Rawson Rd., Brookline, MA 02445 (US). **STEINER, Solomon, S.** [US/US]; 24 Old Wagon Rd., Mount Kisco, NY 10549 (US).

(74) Agents: **PABST, Patrea, L.** et al.; Pabst Patent Group LLP, 1545 Peachtree Street, N.E., Suite 320, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: CONCENTRATED FELBAMATE FORMULATIONS FOR PARENTERAL ADMINISTRATION

(57) Abstract: Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved at high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. For the concentrated suspension, the microparticles have an effective particle size from about 100 nm to about 5 microns, preferably from about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. The formulations described herein can be used to treat a variety of neurological diseases/disorders and/or neurological injury or trauma.



**CONCENTRATED FELBAMATE FORMULATIONS FOR
PARENTERAL ADMINISTRATION
CROSS-REFERENCE TO RELATED APPLICATION**

This application claims priority to U.S. Provisional application no.
5 61/522,811, filed August 12, 2011. The disclosure of which is incorporated
herein by reference.

FIELD OF THE INVENTION

This invention is in the field of formulations of neuroprotective
agents, such as anti-convulsant and/or anti-epileptic agents, for the treatment
10 of neurological disorders, damage, and/or injury, particularly concentrated
solutions and suspensions of carbamazepine, felbamate, and fluorofelbamate.

BACKGROUND OF THE INVENTION

Neurological damage following acute cell death in the brain is a
tremendous health burden without any approved pharmacological
15 intervention. Stroke is the leading cause of serious, long-term disability in
the United States. Additionally, according to the Centers for Disease Control
and Prevention nearly 1.4 million people in the United States sustain a
traumatic brain injury. Also, according to the National Cancer Institute there
are approximately 20 thousand new cases of brain cancer each year in the
20 United States alone. Stroke and traumatic brain injury directly cause
neuronal cell death. Acute treatments for brain cancer including but not
limited to surgical resection and radiation therapy, also yield neuronal cell
death.

When neurons are destroyed they release their contents, including
25 large amounts of the excitatory neurotransmitter glycine, into the
extracellular fluid in high concentrations. Elevated extracellular glycine
levels interact with the strychnine insensitive glycine receptor to open their
attached calcium ion channels. In keeping with the concentration gradient,
calcium ions traverse the open ion channels letting large quantities of
30 calcium into the neuronal cells. Once inside, in high intracellular
concentrations calcium triggers the proteolytic activity of calpain to break
down to an untoward degree, which can lead to cellular injury or cell death.

Seizures occur when neurons exhibit aberrant action potentials. Felbamate is used to treat epileptic seizures by reducing calcium influx, which would otherwise tend to depolarize neurons and increase their propensity to trigger an action potential. Felbamate can stop or reduce the severity of seizures.

However, repeated administration of felbamate, particularly over extended periods of time, can result in severe side effects, such as aplastic anemic and/or liver damage, which can be fatal. Reports have estimated the risk of developing aplastic anemia due to oral administration of felbamate once daily for at least 25 days is 1:3,600 and 1:5,000, of which 30% of the cases are fatal. In the liver, felbamate can be converted to a short-lived toxic metabolite that is believed to be responsible for the observed adverse effects. Fluorofelbamate was developed to avoid the untoward hepatic metabolic pathway of felbamate. For many of the above described neuroprotective indications, patients are unconscious, which makes oral administration challenging if not impossible. Therefore, parenteral formulations are preferred for these therapeutic applications. As well, parenteral formulations avoid first pass metabolism, which lessens the likelihood of reaching toxic concentrations of the undesirable hepatic metabolite of felbamate. However, parenteral formulations administered outside of the vasculature exhibit a lag in absorption time before the blood levels rise to a therapeutic concentration, which can result in further neuronal damage.

There exists a need for formulations of neuroprotective agents, such as the anti-convulsant agents felbamate and fluorofelbamate, which can be administered intravenously in a single administration or over a short period of time, thereby minimizing the potential for adverse side effects associated with felbamate, and which deliver the agent rapidly into circulation in order to reduce, minimize or prevent secondary neuronal damage.

Therefore, it is an object of the invention to provide formulations of neuroprotective agents, which can be administered parenterally in a single or few repeat administrations or over a short period of time, thereby minimizing the adverse side effects associated with these compounds, and minimizing

lag time between neuronal damage and achieving therapeutic concentrations to prevent further neuronal damage.

It is a further object of the invention to provide methods and formulations for treating or preventing epileptic seizures.

- 5 It is a further object of the invention to provide improved methods and formulations for the treatment of neurological disorders.

SUMMARY OF THE INVENTION

- Formulations of a neuroprotective agent (*e.g.*, anti-convulsant and/or anti-epileptic agent, such as carbamazepine, felbamate, and fluorofelbamate) for parenteral administrations are described herein. In one embodiment, the formulation is in the form of microparticles of the agent(s) suspended in a pharmaceutically acceptable carrier suitable for parenteral administration. The microparticles can be prepared by dissolving the agent(s) in a solvent, with or without heating, and then adding the solution of the agent to a non-solvent, with or without cooling. In some embodiments, the solvent is an organic solvent. In other embodiments, the solvent is water or an aqueous solvent, particularly heated water or a heated aqueous solvent. In one embodiment, the solvent is an organic solvent and the non-solvent is water or an aqueous solvent. In another embodiment, the solvent is heated water or an aqueous solvent and the non-solvent is water or an aqueous solvent.
- 10
15
20

- The non-solvent generally contains a surface modifying agent. In particular embodiments, the surface modifying agent is a surfactant. In preferred embodiments, the surfactant has a hydrophilic-lipophilic balance (HLB) of at least about 15, preferably greater than 15. In some embodiments, the surfactant has an HLB of at least about 15, preferably greater than 15 and is a non-ionic surfactant.
- 25

- After formation of the microparticles, the microparticles can be isolated, dried, and stored until use. In these embodiments, if the non-solvent contains a surface modifying agent, such as a surfactant, the surface modifying agent is incorporated into, onto, and/or dispersed throughout the microparticles. If the surface modifying agent is a solid at ambient conditions, or the surface modifying agent is removed prior to final formulation, the microparticles are typically in the form of a dry powder. If
- 30

the surface modifying agent is a liquid at ambient conditions, the microparticles are typically in the form of a slurry. The microparticles can be reconstituted in an appropriate carrier prior to administration. The carrier may contain one or more pharmaceutically acceptable excipients including the surfactant(s). The carrier may also contain dissolved neuroprotective agent (e.g., carbamazepine, felbamate, and fluorofelbamate).

In other embodiments, the microparticles can be administered immediately upon or after formation. For example, if the solvent is sterilized, heated water or aqueous solvent and the non-solvent is (sterilized) water or an aqueous solution, particularly cooled water or aqueous solution, upon mixing, particles form due to the differences in temperature of the solvent and non-solvent. The particles are suspended in the water or aqueous solution, which is suitable for parenteral administration. The suspending medium can optionally contain dissolved neuroprotective agent.

The microparticles have an effective particle size from about 100 nm to about 5 microns, preferably from about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. In particular embodiments, the particle size distribution is at least 80% of the particles by volume have the particle size ranges above.

In still other embodiments, the formulation is in the form of a supersaturated solution of the anti-convulsant and/or anti-epileptic agent. In some embodiments, the drug is dissolved at high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. In particular embodiments, the agent is dissolved in a polyethylene glycol, such as PEG 300, PEG 400, PEG 600, glycerin, propylene glycol, sorbitol, ethylene glycol, or a surfactant, such as polysorbate 20. The resulting supersaturated solution is stable (e.g., no precipitation) for at least one hour, two hours, three hours, four hours, six hours, eight hours, 12 hours, 24 hours, 30 hours, 36 hours, or 48 hours. In preferred embodiments, the resulting supersaturated solution is stable for at least one week, one month, or one year. Prior to administration, the concentrated solution can be diluted in one or more

solvents suitable for parenteral administration, such as water, antimicrobial agents, ethanol, propylene glycol, and combinations thereof.

The formulations described herein can be used to treat a variety of neurological diseases/disorders and/or neurological injury or trauma.

- 5 Exemplary diseases or disorders include, but are not limited to, preventing/reducing seizures, stroke, traumatic brain injury, brain tumor resection, brain tumor irradiation, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder (ADHD), schizophrenia, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain
10 disorder, neuromyotonia, intermittent explosive disorder, and post-traumatic stress disorder.

- In certain embodiments, the formulations described herein are used to treat/prevent seizures and/or other neurological damage, such as stroke, traumatic brain injury, and/or brain tumor resection/irradiation, where rapid
15 delivery of the active agent is required to prevent further damage arising from neuronal injury. In certain embodiments, the formulations described herein are used to prevent secondary neuronal damage accompanying local or global neuronal cell injury or death. For example, the formulations described herein can be used to prevent seizures and/or reduce the length
20 and/or severity of seizures.

- The formulations are administered to provide an effective amount of the active agent. For example, suitable amount of the suspensions and/or solutions are administered to provide a dose of the active agent ranging from 100-2000 mg, preferably 200-1000 mg, more preferably 400-600 mg.
25 However, the appropriate dosage can be determined by the attending physician based on a variety of factors including age and weight of the patient and diseases or disorder to be treated.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

- 30 “Microparticle”, as used herein, refers to any shaped particle with at least one dimension in the range of 10 nanometers to 1,000 microns.

“Neuroprotective”, as used herein refers to any agent that reduces brain cell damage subsequent to primary neuronal cell death.

“Anticonvulsant”, as used herein, refers to any agent that reduces the severity of a seizure.

“Intravenously injectable”, as used herein, refers to any formulation that is capable of being injected into the circulatory system of a mammal.

5 “Diluent”, as used herein refers to an agent that when introduced reduces the concentration of another agent.

“Slurry”, as used herein, refers to any viscous suspension.

“Neuronal”, as used herein, refers to pertaining to the brain.

10 “Primary neuronal injury” refers to cell injury or death directly resulting from a pathophysiology.

“Secondary neuronal cell death” refers to cells that die subsequent to a primary neuronal injury.

15 “Non-solvent” refers to any poor solvent for an agent which is incapable of dissolving more than 1 milligram of the agent in 1 milliliter of the non-solvent.

“Effective particle size” refers to the diameter of a circle with equivalent area to that of the particulate shape.

20 “Supersaturated” refers to solutions that contain a greater quantity of a solute at a given temperature than they would without an additional processing step, such as heating.

As generally used herein “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without
25 excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.

II. Formulations

A. Neuroprotective agents

30 The compositions described herein contain one or more neuroprotective agents, such as anticonvulsant agents and/or anti-epileptic agents. Suitable agents include, but are not limited to, such as carbamazepine, felbamate, fluorofelbamate.

Carbamazepine (CBZ) is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia. It is also used off-label for a variety of indications, including attention-deficit hyperactivity disorder (ADHD), schizophrenia, 5 phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, and post-traumatic stress disorder.

Felbamate (marketed under the brand name Felbatol by Meda Pharmaceuticals Inc.) is an anticonvulsant drug used in the treatment of 10 epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure, due to repeated administration over an extended period of time, has limited its usage to severe refractory epilepsy. 15 Felbamate is an inhibitor of CYP2C19, an isoenzyme of the cytochrome P450 system involved in the metabolism of several commonly used medications. Felbamate interacts with several other anti-epileptic drugs (AEDs), including phenytoin, valproate, and carbamazepine; dosage adjustments may be necessary to avoid adverse effects. Concomitant 20 administration of felbamate and carbamazepine decreases blood levels of both drugs, while increasing the level of carbamazepine-10,11 epoxide, the active metabolite of carbamazepine.

Fluorofelbamate is a derivative of felbamate that was developed to overcome the life-threatening toxicity of felbamate. Fluorofelbamate lacks 25 the reactive intermediate (glutathionine-aldehyde adduct) characterized in felbamate toxicity. In specific embodiments, fluorofelbamate is provided in a parenteral formulation.

The agent can be used as the free acid or free base or as a pharmaceutically acceptable salt. "Pharmaceutically acceptable salt", as 30 used herein, refer to derivatives of the compounds defined by Formula I, II, and III wherein the parent compound is modified by making acid or base salts thereof. Example of pharmaceutically acceptable salts include but are not limited to mineral or organic acid salts of basic residues such as amines;

and alkali or organic salts of acidic residues such as carboxylic acids. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. Such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, tolunesulfonic, naphthalenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic salts.

The pharmaceutically acceptable salts of the compounds can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins, Baltimore, MD, 2000, p. 704; and "Handbook of Pharmaceutical Salts: Properties, Selection, and Use," P. Heinrich Stahl and Camille G. Wermuth, Eds., Wiley-VCH, Weinheim, 2002.

The compounds described herein may have one or more chiral centers and thus exist as one or more stereoisomers. Such stereoisomers can exist as a single enantiomer, a mixture of diastereomers or a racemic mixture.

As used herein, the term "stereoisomers" refers to compounds made up of the same atoms having the same bond order but having different three-dimensional arrangements of atoms which are not interchangeable. The three-dimensional structures are called configurations. As used herein, the term "enantiomers" refers to two stereoisomers which are non-superimposable mirror images of one another. As used herein, the term

"optical isomer" is equivalent to the term "enantiomer". As used herein the term "diastereomer" refers to two stereoisomers which are not mirror images but also not superimposable. The terms "racemate", "racemic mixture" or "racemic modification" refer to a mixture of equal parts of enantiomers. The
5 term "chiral center" refers to a carbon atom to which four different groups are attached. Choice of the appropriate chiral column, eluent, and conditions necessary to effect separation of the pair of enantiomers is well known to one of ordinary skill in the art using standard techniques (see e.g. Jacques, J. et al., "Enantiomers, Racemates, and Resolutions", John Wiley
10 and Sons, Inc. 1981).

Suitable dosages of the active agent are 100-2000 mg, preferably 200-1000 mg, more preferably 400-600 mg. However, the appropriate dosage can be determined by the attending physician based on a variety of factors including age and weight of the patient and diseases or disorder to be treated.

15 The formulations can contain one or more additional active agents that are appropriate to be administered with neuroprotective agents.

B. Concentrated suspensions

In one embodiment, the formulation is the form of a concentrated suspension or slurry. The suspension can be prepared immediately prior to
20 use. For example, as discussed below, microparticles can be prepared by adding a heated aqueous solution of the neuroprotective agent (e.g., anticonvulsants, such as carbamazepine, felbamate, and fluorofelbamate) to an excess of lower temperature sterile water or aqueous solution, such as an aqueous surfactant solution. The resulting microparticles are suspended in
25 an aqueous medium, which can be administered immediately to the patient.

In other embodiments, the microparticles are prepared, isolated, and dried and stored under appropriate conditions. The microparticles can be reconstituted in an appropriate pharmaceutically acceptable carrier prior to administration.

30 The suspending medium optionally contains dissolved neuroprotective agent (e.g., anticonvulsants, such as carbamazepine, felbamate, and fluorofelbamate).

a. Microparticles

The microparticles formed by the methods described herein have reduced crystallinity compared to stock, non-micronized anti-convulsant
5 and/or anti-epileptic agent. The microparticles have an effective particle size of less than about 100 microns. The microparticles preferably have an effective particle size from about 100 nm to about 5 microns, preferably from about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. In particular embodiments, the particle size distribution is
10 at least 80% of the particles by volume have the preferred particle size ranges listed above. The microparticles are rounded, ellipsoidal, and/or spherical.

In some embodiments, the isolated microparticles contain one or more surface modifying agents, preferably surfactants, incorporated into,
15 onto, and/or dispersed throughout the drug particles. Preferably the microparticles contain one or more surface modifying agents adsorbed onto their surface. The surface modifying agent may be present in an amount ranging from 0.0001 to 90% by weight of the total weight of the surface modifying agent and the neuroprotective agent. In some embodiments, the
20 surface modifying agent, preferably surfactant, is a solid at ambient temperature so that the microparticles are in the form of a powder. In other embodiments, the surface modifying agent, preferably surfactant, is a liquid at ambient temperature so that the microparticles form a slurry after isolation from the solvent.

25 i. Surfactants

A variety of surfactants can be used to prepare the microparticles and/or suspensions thereof. Surfactants can be classified as anionic, cationic, amphoteric, and nonionic surfactants and include phospholipids.

Examples of suitable anionic surfactants include, but are not limited
30 to, sodium, potassium, and ammonium salts of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl

sodium sulfosuccinates, such as sodium bis-(2-ethylthioxy)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate, and sodium deoxycholate.

Examples of suitable cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride,
 5 benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine.

Examples of suitable nonionic surfactants include, but are not limited to, ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate,
 10 sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates (TWEENS®), polyoxyethylene octylphenylether, PEG-1000 cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether, POLOXAMER® 401, stearyl monoisopropanolamide, and polyoxyethylene hydrogenated tallow amide.

15 Examples of amphoteric surfactants include, but are not limited to, sodium N-dodecyl- β -alanine, sodium N-lauryl- β -iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.

Suitable phospholipids include, but are not limited to, phosphatidic acids, phosphatidyl cholines with both saturated and unsaturated lipids,
 20 phosphatidyl ethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, lysophosphatidyl derivatives, cardiolipin, and β -acyl- γ -alkyl phospholipids. Examples of phosphatidylcholines include such as dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine dilauroylphosphatidylcholine,
 25 dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoyl-phosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLPC); and phosphatidylethanolamines such as dioleoylphosphatidylethanolamine or 1-
 30 hexadecyl-2-palmitoylglycerophospho-ethanolamine. Synthetic phospholipids with asymmetric acyl chains (e.g., with one acyl chain of 6 carbons and another acyl chain of 12 carbons) may also be used.

Examples of phosphatidylethanol-amines include, but are not limited to, dicaprylphosphatidylethanolamine, dioctanoylphosphatidyl-ethanolamine, dilauroylphosphatidylethanolamine, dimyristoylphosphatidyl-ethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE),

- 5 dipalmitoleoylphosphatidylethanolamine, distearoylphosphatidylethanolamine (DSPE), dioleoylphosphatidylethanolamine, and dilineoylphosphatidylethanol-amine.

Examples of phosphatidylglycerols include, but are not limited to, dicaprylphosphatidylglycerol, dioctanoylphosphatidylglycerol, dilauroylphosphatidylglycerol, dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), dipalmitoleoylphosphatidylglycerol, distearoylphosphatidylglycerol (DSPG), dioleoylphosphatidylglycerol, and dilineoylphosphatidylglycerol.

- 15 In a preferred embodiment, the surfactant is a polysorbate. In one embodiment, the surfactant has an HLB of at least 15, preferably greater than 15. In other embodiments, the surfactant has an HLB of at least 15, preferably greater than 15 and is a non-ionic surfactant. In one embodiment, the surfactant is a polysorbate. In a preferred embodiment, the surfactant is polysorbate 20.

- 20 The suspension can contain one or more pharmaceutically acceptable excipients including, but not limited to, pH modifying agents, dispersing agents, tonicity modifying agents, plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, bioavailability enhancers, and combinations thereof.

25 **C. Concentrated supersaturated solutions**

- In other embodiments, the formulation is in the form of a concentrated solution. In some embodiments, the drug is dissolved at high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. In particular embodiments, the neuroprotective agent (e.g., anticonvulsants, such as carbamazepine, felbamate, and fluorofelbamate) is dissolved in one or a combination of a polyethylene glycol, such as PEG 300, PEG 400, PEG 600, glycerin, propylene glycol, sorbitol, ethylene

glycol, or a surfactant, such as polysorbate 20. The resulting supersaturated solution is stable (e.g., no precipitation) for at least one hour, two hours, three hours, four hours, six hours, eight hours, 12 hours, 24 hours, 30 hours, 36 hours, or 48 hours. Prior to administration, the concentrated solution can
5 be diluted in one or more solvents suitable for parenteral administration, such as water, antimicrobial agents, ethanol, propylene glycol, and combinations thereof.

The solution can contain one or more pharmaceutically acceptable excipients including, but not limited to, pH modifying agents, tonicity
10 modifying agents, plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, bioavailability enhancers, and combinations thereof. The diluting solvent may contain one or more surfactants, such as those described above.

III. Methods of Making

15 A. Concentrated microparticle suspensions

In some embodiments, a neuroprotective agent (e.g., anticonvulsants, such as carbamazepine, felbamate, and fluorofelbamate) is dissolved in a suitable solvent or solvent mixture. In some embodiments, the solvent or solvent mixture is water or an aqueous solvent. In other embodiments, the
20 solvent or solvent mixture is an organic solvent. Suitable organic and aqueous solvent include, but are not limited to, dimethyl sulfoxide, heated water, glycerin and mixtures thereof.

The neuroprotective agent (e.g., anticonvulsants, such as carbamazepine, felbamate, and fluorofelbamate) solution is then introduced
25 into an excess of a non-solvent for the neuroprotective agent, which is miscible with the solvent. Suitable non-solvents include, but not limited to water, an aqueous solution of a surfactant (see the surfactants described above), and an aqueous surfactant (see the surfactants described above) solution containing dissolved neuroprotective agent. In some embodiments,
30 the aqueous receiving solution is stirred. When the solvent mixes with the non-solvent, the mixture presents unfavorable solubility conditions for the neuroprotective agent (e.g., anticonvulsants, such as carbamazepine,

felbamate, and fluorofelbamate) causing it to leave solution creating a particulate suspension.

In particular embodiments, the resultant particle size distribution is at least eighty volume percent between 100 nanometers and five microns in effective particle size, more preferably between fifty nanometers and three microns in effective particle size, and most preferably between 10 nanometers and two microns in effective particle size.

In embodiments employing an organic solvent, the particle suspension can be stirred, in the presence of absence of heating and/or vacuum, until a sufficient quantity of the organic solvent has evaporated to effect particle formation.

In particular embodiments, the non-solvent contains a surface modifying agent, such as a surfactant. In some embodiments, the surfactant has a hydrophilic lipophilic balance (HLB) at least about fifteen. In more particular embodiments, the surfactant has an HLB of greater than 15. Suitable surfactants include, but are not limited to, polysorbate 20. The concentration of surfactant during particle formation is generally greater than 0.05 weight per volume percent, more preferably greater than 0.1 weight per volume percent, and most preferably greater than 0.4 weight per volume percent. However, the concentration can be lower or greater than these values dependent on the solvent, non-solvent, and surfactant that are used.

In some embodiments, stock felbamate, fluorofelbamate, or other carbamazepine powder is suspended in an aqueous surfactant solution. The aqueous felbamate suspension is then heated to at least approximately 50°, preferably to at least approximately 60°, and more preferably to at least approximately 70° Celsius until the felbamate dissolves. The heated felbamate solution is then allowed to cool in the presence or absence of an external cooling element and in the presence or absence of stirring. As the temperature decreases, the felbamate precipitates from solution to form microparticles. In preferred embodiments, the resultant felbamate particle size distribution is at least eighty volume percent between 100 nanometers and five microns in effective particle size, more preferably between 50 nanometers and three microns in effective particle size, and most preferably

between 10 nanometers and two microns in effective particle size. In particular embodiments, the particle size distribution is at least 80% of the particles by volume have the particle size ranges above.

In embodiments in which the particle size is unstable, the resultant
5 felbamate suspension can be rapidly frozen by any one or a combination of the following including, but not limited to, electronic refrigeration, introduction onto dry ice, and introduction into liquid nitrogen. The frozen suspension can be lyophilized to produce a felbamate microparticle slurry in the remaining surfactant, provided the surfactant is liquid in ambient
10 conditions. In some embodiments, the surfactant is a solid in ambient conditions thereby creating a dry powder after lyophilization.

In preferred embodiments, the concentration of surfactant in solution prior to drying is reduced such that when the resultant suspension is lyophilized, it produces a dry powder. The resultant slurry or dry powder can
15 be resuspended to create a concentrated felbamate microparticle suspension for parenteral administration or stored as a two part suspension for parenteral administration after resuspension.

1. One part suspensions

In embodiments that produce dilute suspensions of the
20 neuroprotective agent (e.g., anticonvulsants, such as carbamazepine, felbamate, and fluorofelbamate), concentration of the suspension can be achieved by any or a combination of the following including, but not limited to, centrifugation, decanting, and resuspension in a lesser volume; drying by means of lyophilization, spray drying, air drying, or other means, followed
25 by resuspension in a lesser volume; and reduction in the volume of the suspension media using a spin column. In preferred embodiments, the resultant suspension concentration is approximately or greater than five weight percent, more preferably approximately or greater than ten weight per volume percent, and most preferably approximately or greater than twenty
30 weight per volume percent. In some preferred embodiments, the suspending media is one or a combination of the following including, but not limited to, water for injection, sterile phosphate buffered saline, a sterile aqueous surfactant solution, and a sterile aqueous antimicrobial solution.

2. Two part suspensions

In embodiments producing a microparticle slurry or dry powder, the resultant slurry or dry powder formulation can be stored separately from its suspending media until administration. In some embodiments the slurry or dry powder can be stored separately from the resuspension media in separate containers. In preferred embodiments the slurry or dry powder is stored dry within one compartment of a two-compartment syringe. The resuspension media is stored in a separate compartment within the syringe. Prior to administration, the slurry or powder is resuspended in the resuspension media for administration as a single suspension.

B. Concentrated solutions

In some embodiments, the neuroprotective agent (e.g., anticonvulsants, such as carbamazepine, felbamate, and fluorofelbamate) is dissolved at high concentrations, e.g. greater than about one weight percent, preferably greater than about five weight percent, and more preferably greater than about ten weight percent, in a solvent suitable for parenteral administration (e.g., injection), more preferably suitable for intravenous injection.

In a specific embodiment, the agent is added above its solubility limit in one or more solvents. The agent is typically added to the one or more solvents. Suitable solvents include, but are not limited to, polyethylene glycol 300, polyethylene glycol 400, and polyethylene glycol 600. The solution of the agent is heated, for example to a temperature of at least about 50°C, preferably at least 60°C, and more preferably at least about 70°C until the felbamate, fluorofelbamate, or carbamazepine dissolves and is then cooled, for example to room temperature, while remaining in solution to form a stable, supersaturated solution. In this embodiment, the resultant supersaturated solution remains in solution at room temperature for at least one hour where the concentration of agent in the supersaturated solution is at least 5%, preferably at least 10%, more preferably at least 15%, most preferably 20% weight per volume. The upper limit for the concentration of the agent in the supersaturated solution preferably is less than 35% weight by volume, less than 20% weight by volume, or less than 15% weight by

volume. In preferred embodiments the agent in the super saturated solution is felbamate or fluorofelbamate.

In certain embodiments, the supersaturated solution remains stable for at least one week, one month, or one year.

5 In another embodiment, the agent is dissolved in glycerin heated to above approximately 100°C and then cooled to ambient storage temperatures to form a supersaturated solution. Since felbamate and fluorofelbamate have a solubility in water of less than one milligram per milliliter, the ability to create a stable supersaturated solution of felbamate in an intravenously
10 acceptable solvent is unexpected.

In some embodiments, felbamate is dissolved in heated polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, propylene glycol, sorbitol, ethylene glycol, or polysorbate 20 in concentrations greater than would enter solution in water at 25°C.

15 In some embodiments, prior to injection, the solution of the agent can be diluted with another injectable solvent including, but not limited to, water, one or more antimicrobial agents, ethanol, and propylene glycol, and combinations thereof.

IV. Methods of Use

20 The formulations described herein can be used to treat a variety of neurological diseases/disorders and/or to prevent secondary neuronal injury following neurological hypoxia, injury or trauma. Exemplary diseases or disorders include, but are not limited to, preventing/reducing seizures, stroke, traumatic brain injury, brain tumor resection, brain tumor irradiation, bipolar
25 disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder (ADHD), schizophrenia, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, and post-traumatic stress disorder.

In certain embodiments, the formulations described herein are used to
30 treat/prevent seizures, status epilepticus and/or other neurological damage, such as stroke, traumatic brain injury, and/or brain tumor resection/irradiation, where rapid delivery of the active agent is required to prevent further damage arising from neuronal injury. For example, the

formulations described herein can be used to prevent seizures and/or reduce the length and/or severity of seizures.

Felbamate has been used to treat or prevent neurological diseases and/or injury. However, long-term felbamate administration can result in
5 aplastic anemia, a sometime fatal side effect. The risk of aplastic anemia associated with chronic oral felbamate dosing has been reported as between 1:3,600 and 1:5,000, of which 30% of the cases are fatal.

In contrast, the suspensions and solutions described herein are administered parenterally as a single administration or a short course of
10 treatment which is less than 48 hours in duration, preferably less than 8 hours, more preferably less than 6 hours. Aplastic anemia has not been shown to develop after a single administration of felbamate. The formulations described herein provide rapid delivery of the active agent to prevent further damage resulting from neurological injury or damage.

15 The formulations are administered to provide an effective amount of the active agent. For example, suitable amount of the suspensions and/or solutions are administered to provide a dose of the active agent ranging from 100-2000 mg, preferably 200-1000 mg, more preferably 400-600 mg. However, the appropriate dosage can be determined by the attending
20 physician based on a variety of factors including age and weight of the patient and diseases or disorder to be treated.

Examples

Example 1. Preparation of microparticles using organic solvent method

25 Felbamate was dissolved in dimethyl sulfoxide to create a five weight per volume percent solution. The felbamate solution was introduced into one hundred times the volume of a one weight per volume percent polysorbate 20 aqueous solution stirred at 1,500 revolutions per minute using an overhead mixer equipped with an impeller blade. The resultant microparticles of
30 felbamate were imaged using SEM. The particles appeared round in shape, suitable for injection. Under the same experimental conditions, Span 80 was substituted for polysorbate 20. The felbamate formed crystals, which are unsuitable for injection.

Felbamate was dissolved in glycerin heated above 120°C to create a 5% weight per volume solution. The felbamate solution was introduced into one hundred times the volume of a one weight per volume percent polysorbate 20 aqueous solution stirred at 1,500 revolutions per minute using an overhead mixer equipped with an impeller blade. The resultant microparticles of felbamate were imaged using SEM. The particles appeared round in morphology and were significantly smaller, on the order of microns as compared to hundreds of microns for native felbamate powder.

Example 2. Washing and resuspension of microparticles

Felbamate microparticles were centrifuged in a refrigerated centrifuge spinning at 8,000 revolutions per minute for a period of twenty minutes. The supernatant was substantially removed enabling the felbamate microparticles to be resuspended in any desired media.

Example 3. Preparation of felbamate microparticles using the aqueous solvent method

Felbamate was dissolved in water heated to 90°C to create a five weight per volume percent solution. The felbamate solution was introduced into one hundred times the volume of a one weight per volume percent polysorbate 20 aqueous solution stirred at 1,500 revolutions per minute using an overhead mixer equipped with an impeller blade.

Example 4. Preparation of felbamate microparticles in the presence of a surface modifying agent

Felbamate was dissolved in an aqueous solution of polysorbate 20 having a concentration of one weight percent and heated to 90°C. The solution was then cooled to allow the felbamate to precipitate, thereby forming microparticles.

Example 5. Drying Felbamate Suspensions

Vessels containing aqueous or predominantly aqueous suspensions of felbamate were introduced into a dewar containing liquid nitrogen to rapidly freeze the suspension. The frozen suspension was then lyophilized to produce either a felbamate slurry or dry powder.

Example 6. Felbamate Supersaturated Solution

Felbamate was added at a concentration of up to 20 weight per volume percent to polyethylene glycol 300 and polyethylene glycol 400.

- 5 Solutions were heated above 70°C after which the felbamate dissolved. Upon cooling the samples in ambient conditions to room temperature, which was approximately 25°, samples up to approximately 12.5 weight per volume percent remained in solution for at least eight months. The sample also remained in solution when heated or cooled to 40°C, 4°C, and -20°C for 30
10 minutes and then allowed to return to 25°C.

Example 7. Felbamate Supersaturated Solution Mixtures

Felbamate was added at a concentration of up to 10 weight per volume percent in 65 volume per volume percent polyethylene glycol 300, 20 volume per volume percent polyethylene glycol 400, and 15 volume per
15 volume percent propylene glycol. In a separate experiment, felbamate was added at a concentration of up to 10 weight per volume percent in 65 volume per volume percent polyethylene glycol 300, 20 volume per volume percent polyethylene glycol 400, 10 volume per volume percent propylene glycol, and 5 volume per volume percent polyethylene glycol 600.

- 20 Solutions were heated above 70°C after which the felbamate dissolved. Upon cooling the samples in ambient conditions to room temperature, e.g., approximately 25°C, the sample remained in solution for at least 1 day.

Example 8. Felbamate Solution Injection

- 25 A supersaturated 10 weight per volume percent felbamate solution in PEG 300 was injected into 37°C phosphate buffered saline. No solid particles were observed. Additional felbamate supersaturated solution at the same concentration was added 10 microliters at a time without forming solid particles up to at least 50 microliters. This indicates that felbamate will
30 remain in suspension in blood plasma well in excess of the standard therapeutic doses of 400 to 600 mg per dose.

Example 9. Fluorofelbamate Supersaturated Solution

Fluorofelbamate was added at a concentration of 10 weight per volume percent to polyethylene glycol 300. Solutions were heated above
5 approximately 80°C after which the fluorofelbamate dissolved. Upon cooling the samples in ambient conditions to room temperature, which was approximately 25°, the sample remained in solution for at least 1 month.

We claim:

1. A pharmaceutical composition comprising a supersaturated solution of a neuroprotective agent or a concentrated suspension of the microparticles of the neuroprotective agent in a pharmaceutically acceptable carrier suitable for parenteral administration,
wherein the neuroprotective agent is an anti-convulsant agent and/or anti-epileptic agent.
2. The composition of claim 1, wherein the neuroprotective agent is selected from carbamazepine, felbamate, or fluorofelbamate.
3. The composition of claim 2, wherein the neuroprotective agent is felbamate.
4. The composition of claim 2, wherein the neuroprotective agent is fluorofelbamate.
5. The composition of claim 2, wherein the neuroprotective agent is carbamazepine.
6. The composition of claim 1, wherein the composition is a supersaturated solution of a neuroprotective agent in a pharmaceutically acceptable carrier suitable for parenteral administration.
7. The composition of claim 6, wherein the concentration of the agent is at least about 1% weight by volume, at least 5% weight by volume, more preferably at least 10% weight by volume, most preferably at least about 12.5% by weight by volume.
8. The composition of claim 7, wherein the agent is felbamate or fluorofelbamate, and wherein the concentration of the agent is less than 35% weight by volume, less than 20% weight by volume, or less than 15% weight by volume.
9. The composition of any one of claims 6 to 8, wherein the room temperature stability of the supersaturated solution is greater than 1 month, preferably greater than 6 months, more preferably greater than one year.
10. The composition of any one of claims 6 to 9, wherein the solvent for the solution is a polyethylene glycol.

11. The composition of claim 10, wherein the polyethylene glycol is PEG 300, 400, or 600.
12. The composition of any one of claims 6 to 9, wherein the solvent for the solution is ethylene glycol or propylene glycol.
13. The composition of claim 12, wherein the solvent for the solution is propylene glycol.
14. The composition of any one of claims 6 to 9, wherein the solvent for the solution is mixture of any combination of at least two solvents selected from polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, and glycerin.
15. The composition of claim 1, wherein the composition is a concentrated suspension of the microparticles of the neuroprotective agent in a pharmaceutically acceptable carrier suitable for parenteral administration,
wherein the microparticles have a surface modifying agent adsorbed on the surface thereof,
wherein the surface modifying agent is present in an amount of 0.0001 to 90% by weight of the total weight of the surface modifying agent and the neuroprotective agent, and
wherein the microparticles have an effective particle size of less than about 100 microns.
16. The composition of claim 15, wherein the concentration of the particles in the suspension is at least 5% weight by volume, preferably at least 10% weight by volume, more preferably at least 15% weight by volume, more preferably at least 20% weight by volume.
17. The composition of claim 15 or 16, wherein the carrier for the suspension comprises water.
18. The composition of claim 17, wherein the carrier for the suspension is an aqueous solution of a second surface modifying agent.
19. The composition of any one of claims 15 to 18, wherein the first and/or second surface modifying agent is a surfactant.
20. The composition of any one of claims 1 to 19, wherein the carrier further contains one or more antimicrobial agents.

21. The composition of any one of claims 1 to 20, further containing one or more pharmaceutically acceptable excipients.
22. The composition of any one of claims 1 to 21, wherein the dose of the neuroprotective agent is from 100-2000mg, preferably 100-1000 mg, more preferably from 400-600 mg.
23. Microparticles of a neuroprotective agent, wherein the microparticles have a surface modifying agent adsorbed on the surface thereof, wherein the surface modifying agent is present in an amount of 0.0001 to 90% by weight of the total weight of the surface modifying agent and the neuroprotective agent, wherein the microparticles have an effective particle size of less than about 100 microns, wherein the neuroprotective agent is an anti-convulsant agent and/or anti-epileptic agent.
24. The microparticles of claim 23, wherein the neuroprotective agent is an anti-convulsant and/or anti-epileptic agent selected from carbamazepine, felbamate, or fluorofelbamate.
25. The microparticles of claim 23, wherein the agent is carbamazepine.
26. The microparticles of claim 23, wherein the agent is felbamate.
27. The microparticles of claim 23, wherein the agent is fluorofelbamate.
28. The microparticles of any one of claims 23-27, wherein the effective particle size is from 100 nanometer to about 5 microns, preferably from about 50 nanometers to about 3 microns, more preferably from about 10 nanometers to about 2 microns.
29. The microparticles of any one of claims 23-28 wherein the particles are rounded, ellipsoidal, or spherical.
30. The microparticles of any one of claims 23-29, wherein the particles have reduced crystallinity compared to stock, non-micronized anti-convulsant and/or anti-epileptic agent.
31. The microparticles of any one of claims 23-30, wherein the surface modifying agent is a surfactant.
32. The microparticles of claim 31, wherein the surfactant is a solid at ambient temperature and the particles are in the form of a dry powder.
33. The microparticles of claim 31, wherein the surfactant is a liquid at ambient temperature and the particles are in the form of a slurry.

34. The microparticles of any one of claims 31-33, wherein the surfactant has an HLB value of at least about 15.
35. The microparticles of claim 34, wherein the surfactant is non-ionic.
36. The microparticles of claim 31, wherein the surfactant is polysorbate 20.
37. A method for making the microparticles of any one of claims 23-36 comprising mixing a solution of the anti-convulsant and/or anti-epileptic agent in a solvent into a solution of the surface modifying agent that is a non-solvent for the carbamate neuroprotective to form a suspension of microparticles having an effective particle size less than 100 microns.
38. The method of claim 37, wherein the ratio of the non-solvent to the solvent is at least 20:1, preferably at least 50:1, more preferably at least 100:1.
39. The method of claims 37 or 38, wherein the surface modifying agent is a surfactant and the surfactant concentration is at least 0.1 weight per volume, preferably at least 0.4 weight per volume, more preferably at least 1.0 weight per volume.
40. The method of any one of claims 37-39, wherein the surfactant stabilizes the suspension of microparticles by maintaining the mean particle size within 30%, preferably within 20%, more preferably within 10% of the initial mean particle size upon formation of the microparticles.
41. The method of any one of claims 37-40, wherein the solvent is an organic solvent.
42. The method of claim 41, wherein the organic solvent is dimethyl sulfoxide.
43. The method of claim 41, wherein the organic solvent is glycerin heated to a temperature of at least about 90°C, preferably at least 120°C, more preferably at least 150°C.
44. The method of any one of claim 37-40, wherein the solvent is water heated to a temperature of at least about 50°C, preferably at least 60°C, more preferably at least 70°C.
45. The method of any one of claims 37-43, wherein the non-solvent is water.

46. The method of any one of claims 37-43, wherein the non-solvent is an aqueous solution of the surface modifying agent.
47. The method of claim 46, wherein the aqueous solution is an aqueous solution of a surfactant.
48. The method of any one of claims 37-47, wherein a heated mixture of the solution of the agent and the aqueous solution of the surface modifying agent is cooled to effect formation of the microparticles.
49. The method of any one of claims 37-48, wherein the non-solvent contains dissolved or dispersed neuroprotective agent.
50. A method for treating a neurological disease, injury, or trauma, comprising administering an effective amount of the composition of any one of claims 1-20.
51. The method of claim 50, wherein the disease is epilepsy.
52. The method of claim 50, wherein the injury or trauma resulted from a seizure.
53. The method of claim 50, wherein the injury or trauma resulted from traumatic brain injury.
54. The method of claim 53, wherein the injury or trauma resulted from hypoxia or ischemia.
55. The method of claim 53, wherein the injury or trauma resulted from stroke.
56. A method for preventing further secondary neuronal damage resulting from a neurological disease, disorder, or trauma comprising administering an effective amount of the composition of any one of claims 1-20.
57. The method of claim 56, wherein the injury or trauma resulted from traumatic brain injury.
58. The method of claim 56, wherein the injury or trauma resulted from hypoxia or ischemia.
59. The method of claim 56, wherein the injury or trauma resulted from stroke.



(51) International Patent Classification:

A61K 31/55 (2006.01) A61K 9/14 (2006.01)
A61K 31/27 (2006.01) A61P 25/00 (2006.01)
A61K 9/16 (2006.01)

(21) International Application Number:

PCT/US2012/050148

(22) International Filing Date:

9 August 2012 (09.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/522,811 12 August 2011 (12.08.2011) US

(71) Applicant (for all designated States except US): **PEROSPHERE INC.** [US/US]; 171 Meeting Street, Providence, RI 02912 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAKHURU, Sasha, H.** [US/US]; 200 Exchange Street, Unit 1612, Providence, RI 02903 (US). **LAULICHT, Bryan, E.** [US/US]; 100 Landsdowne Street, Apt. 1501, Cambridge, MA 02139 (US). **MATHIOWITZ, Edith** [US/US]; 184 Rawson Rd., Brookline, MA 02445 (US). **STEINER, Solomon, S.** [US/US]; 24 Old Wagon Rd., Mount Kisco, NY 10549 (US).

(74) Agents: **PABST, Patrea, L.** et al.; Pabst Patent Group LLP, 1545 Peachtree Street, N.E., Suite 320, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

25 April 2013

(54) Title: CONCENTRATED FELBAMATE FORMULATIONS FOR PARENTERAL ADMINISTRATION

(57) Abstract: Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved at high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. For the concentrated suspension, the microparticles have an effective particle size from about 100 nm to about 5 microns, preferably from about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. The formulations described herein can be used to treat a variety of neurological diseases/disorders and/or neurological injury or trauma.



A. CLASSIFICATION OF SUBJECT MATTER***A61K 31/55(2006.01)i, A61K 31/27(2006.01)i, A61K 9/16(2006.01)i, A61K 9/14(2006.01)i, A61P 25/00(2006.01)i***

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K 31/55; A61K 9/14; A61K 9/00; A61K 31/47; B02C 17/16; A61K 47/30; A61K 9/16; A61K 31/38; A61K 31/655; A61K 31/663

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: neuroprotective, carbamazepine, felbamate, fluorofelbamate, carrier, microparticle, suspension

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y A	WO 2009-017825 A2 (THE GENERAL HOSPITAL CORPORATION et al.) 05 February 2009 See pages 7-9, 14-16, 19-25 and claims 1, 7, 8.	1,15-18,23,28 2-8,24-27 9
Y	US 2002-0003179 A1 (VERHOFF, F. H. et al.) 10 January 2002 See paragraphs 131, 139, 165, 166, 203, and 204.	2,3,5,24-26
Y	US 2006-0160776 A1 (STEPHENSON, D. T. et al.) 20 July 2006 See paragraphs 425 and 441-444.	4,27
Y	US 2009-0311325 A1 (JANSSENS, S. et al.), 17 December 2009 See abstract and paragraphs 21-26, 30, 51.	6-8
A	US 7906145 B2 (CASTAN, C. et al.) 15 March 2011 See the whole document.	1-9,15-18,23-28



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 FEBRUARY 2013 (15.02.2013)

Date of mailing of the international search report

18 FEBRUARY 2013 (18.02.2013)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon Metropolitan
City, 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

Kim, Sang Joon

Telephone No. 82-42-481-5621



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2012/050148**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 50-59
because they relate to subject matter not required to be searched by this Authority, namely:

Claims 50-59 pertain to methods of treatment of the human body by therapy, and thus relate to a subject matter which this ISA is not required, under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv), to search.
2. ☒ Claims Nos.: 11, 13, 32, 33, 35, 36, 38, 42, 43, 47, 51-55, 57-59
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claims 11, 13, 32, 33, 35, 36, 38, 42, 43, 47, 51-55, and 57-59 are unclear under PCT Article 6, because they directly or indirectly refer to another claim contrary to PCT Rule 6.4(a).
3. ☒ Claims Nos.: 10, 12, 14, 19-22, 29-31, 34, 37, 39-41, 44-46, 48-50, 56
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2012/050148

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009-017825 A2	05.02.2009	US 2012-053220 A1	01.03.2012
US 2002-0003179 A1	10.01.2002	US 6604698 B2	12.08.2003
US 2006-0160776 A1	20.07.2006	WO 2004-105699 A2	09.12.2004
US 2009-0311325 A1	17.12.2009	CA 2642757 A1	18.10.2007
		CN 101460148 A	17.06.2009
		EP 2004142 A2	24.12.2008
		GB 0607105 D0	17.05.2006
		IL 194635 D0	03.08.2009
		JP 2009-533357 A	17.09.2009
		WO 2007-115381 A2	18.10.2007
		ZA 200808556 A	25.11.2009
US 7906145 B2	15.03.2011	AT 419840 T	15.01.2009
		AU 2003-246792 A1	20.10.2003
		BR 0309142 A	01.02.2005
		CA 2480826 A1	16.10.2003
		CN 1652781 C0	10.08.2005
		DE 60325709 D1	26.02.2009
		EP 1492511 A2	05.01.2005
		ES 2320438 T3	22.05.2009
		HK 1079448 A1	11.06.2010
		IL 164222 A	31.07.2011
		JP 2005-527573 A	15.09.2005
		KR 10-1061351 B1	31.08.2011
		MX PA04009968 A	13.12.2004
		PT 1492511 E	09.04.2009
		WO 03-084518 A2	16.10.2003

摘 要

本發明描述了一種神經保護劑的注射用製劑。所述製劑是濃縮（過飽和）溶液或微粒的濃縮懸浮液的形式。懸浮液介質或溶液溶劑載體也可含有溶解的神經保護劑。在所述過飽和溶液中，所述神經保護劑以至少約 1%重量比、5%重量比、10%重量比、15%重量比、或 20%重量比的高濃度溶解於適於注射用的溶劑中。在所述濃縮懸浮液中，所述微粒的有效粒徑為約 100 納米至約 5 微米，優選為約 50 納米至約 3 微米，更優選為約 10 納米至 2 微米。本發明描述的製劑可用於治療多種神經疾病/病症和/或神經損傷或創傷。